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Abstract
Background: Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are persistent herpesviruses that have various
immunomodulatory effects on their hosts. Both viruses are usually acquired in infancy in Sub-Saharan Africa, a region
where childhood vaccines are less effective than in high income settings. To establish whether there is an association
between these two observations, we tested the hypothesis that infection with one or both viruses modulate antibody
responses to the T-cell independent meningococcal polysaccharide vaccine and the T-cell dependent measles vaccines.
Methodology/Principal Findings: Infection with EBV and CMV was diagnosed by the presence of virus-specific IgM in the
peripheral blood or by the presence of IgG at higher levels than that found in umbilical cord blood. Anti-meningococcus IgG
and IgM were quantified by ELISA. Anti-measles antibody responses were quantified by haemagglutinin antibody inhibition
assay. Infants infected with EBV had reduced IgG and IgM antibody responses to meningococcal polysaccharides and to
measles vaccine. Infection with CMV alone predicted no changes in the response to meningococcal polysaccharide. While
CMV alone had no discernable effect on the antibody response to measles, the response of infants infected with both CMV
and EBV was similar to that of infants infected with neither, suggesting that the effects of CMV infection countered the
effects of EBV on measles antibody responses.
Conclusions: The results of this exploratory study indicate that infection with EBV is associated with reduced antibody
responses to polysaccharides and to measles vaccine, but suggest that the response to T-cell dependent antigens such as
measles haemagglutinin may be restored by infection with CMV.
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Introduction
Infant vaccination is one of the most important strategies to
combat infectious disease worldwide. However, it has been known
for four decades that the efficacy of infant vaccines in Sub-Saharan
Africa is lower than in high income settings [1] and that
intercurrent infections like malaria may influence antibody
responses [2,3]. For instance, the efficacy of the live attenuated
measles vaccine is typically over 90% in Europe and North
America [4–6], but below 70% in West Africa [7–9].
In Sub-Saharan Africa, infection with the herpesviruses Epstein-
Barr virus (EBV) and cytomegalovirus (CMV) usually occurs during
infancy [10–12], after which they establish lifelong infection [13,14].
Although infection is usually asymptomatic, both viruses have
powerful effects on the lymphocyte populations involved in vaccine-
mediated immunity. EBV infects B-cells and during acute infection,
up to 50% of B-cells may be infected [15]. While EBV infection is
usually asymptomatic in healthy individuals, it can cause severe
disease in immunocompromised individuals and coupled with
chromosomal translocations, causes Burkitt’s lymphoma Burkitt’s
lymphoma in infants whose immune systems have been suppressed
by malaria [16,17]. In the absence of disease, EBV infected B-cells
accumulate a relatively high number of mutations which suggests
that EBV may influence the B-cell compartment even in the
absence of clinical disease [18]. The effect of EBV infection on B-
cell responses to vaccines or concurrent infections is unknown.
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Unlike EBV, CMV has a powerful influence on T-cells even
though T-cells are not a major target for CMV infection [19]. The
T-cell populations of CMV-infected individuals show considerably
higher levels of differentiation [20–23], even among young infants
who are still receiving childhood vaccinations [24]. These effects
vary with age as CMV-induced differentiation in the elderly is
associated with reduced subpopulations of naı¨ve T-cells and poor
vaccine responses [23,25], but infected infants show no such
evidence of reduction of the naı¨ve T-cell pool or of CMV-
associated reduction in T-cell response to measles vaccine [26].
Polysaccharide vaccines stimulate B-cells independently of T-
cells, suggesting that they may be particularly vulnerable to
modulation by EBV. Although the meningococcus polysaccharide
does not induce lasting immunity if administered before four years
[27], the WHO still recommends vaccination irrespective of age to
contain the outbreaks of meningococcal meningitis that periodi-
cally sweep the Sub-Saharan ‘meningitis belt’ [28,29] and so it
remains a valuable tool in child health.
By contrast, the live attenuated measles vaccine induces a broad
range of T-cell and antibody responses [30,31] so is unlikely to be
so vulnerable to any one mechanism of modulation.
As early life CMV and EBV infection and relatively low vaccine
efficacy are both characteristic of Sub-Saharan Africa, we
hypothesised an association between CMV and EBV infection in
infancy and reduced antibody responses to vaccines. We therefore
quantified their influence on antibody responses to the polysac-
charide vaccine against Neisseria meningitidis (meningococcus) and
the live attenuated measles vaccine. We recruited infants from an
ongoing cohort in a peri-urban area of The Gambia and
administered the vaccines at nine months of age. Two months
later, we compared the vaccine antibody responses of infants
infected with CMV and/or EBV to those who remained
uninfected.
Materials and Methods
Subjects and vaccinations
Infants were recruited at birth from the maternity ward of
Sukuta Health Centre. Informed consent was obtained from their
mothers and documented by signature or thumb print. Recruit-
ment was restricted to healthy singletons, defined by a birth weight
of at least 1.8kg and no congenital abnormalities, and whose
mothers had not been admitted for hospital treatment during
pregnancy or labour.
The area served by Sukuta Health Centre is peri-urban, and the
population is characterised by low income and crowded
accommodation. Breast feeding is usually continued well into the
second year and 50% of infants are infected with CMV by 10
weeks of age [10]. The HIV status of study subjects was unknown,
but adult prevalence in the region was below 2.5% at the time of
the study [32], so is unlikely to be a significant confounder of this
study. Exposure to malaria is low [33] and no cases of measles
have been reported over the last 7 years. No children were
clinically ill at the time of vaccination, and no outbreaks of
measles, meningitis, Respiratory syncytial virus or Rotavirus
occurred during the study.
All study subjects received childhood vaccinations according to
the Expanded Program of Immunisation, which included
inoculation with the live attenuated Edmonston-Zagreb strain of
the measles virus (Serum Institute of India) at nine months. In
addition, all infants were vaccinated with 50 mg each of
meningococcus subtypes A and C capsular polysaccharide
(Sanofi-Pasteur), also at nine months. All infants received a second
dose of meningococcus conjugate C vaccine (kindly donated by
Wyeth-Lederle) between three and four years of age to ensure
continued protection.
The study was approved by the Gambia Government/MRC
ethics committee.
Sampling schedule
Umbilical cord blood was collected from 224 infants at birth,
and heparinised plasma was stored. At nine months, 1 ml of blood
was collected into a serum separator tube (Becton-Dickinson) for
serum collection from 194 infants. At eleven months, 4 ml of
blood was collected for serum antibody measurements from 182
subjects and full laboratory data was available for 178 subjects
(Fig. 1). Loss to follow–up was mainly due to migration (46%) or
refusal to be bled (18%). All plasma and serum samples were
stored at 250uC or below, and subjected to no more than three
freeze-thaw cycles in the course of the study.
Diagnosis of EBV and CMV
As many of the umbilical cord blood plasma samples contained
substantial levels of maternally derived anti-EBV and CMV IgG, it
was not possible to base diagnosis at nine or eleven months purely
on IgG serostatus.
When infants received the measles and meningococcus vaccines
at nine months, infants were classified as infected if they met one of
two criteria, which were 1/virus-specific IgG levels exceeded the
levels in their umbilical cord blood or 2/a detectable level of virus-
specific IgM. Infants were classified as uninfected if they met one
of three criteria: 1/virus-specific IgG and IgM levels were
undetectable at the time of sampling, 2/virus-specific IgG and
IgM levels were both undetectable at eleven months, as infants
infected at nine months would have an antibody response by
eleven months, or 3/virus-specific IgG levels were detectable but
below cord blood levels at nine months while IgM levels converted
from undetectable to detectable between nine and eleven months.
Two months after receiving the measles and meningococcus
vaccines, at eleven months of age, infants were classified as
infected if they met one of three criteria: 1/virus-specific IgG levels
exceeded the levels in their umbilical cord blood, 2/if they had
detectable levels of virus-specific IgM, or 3/if they had been
classified as infected at nine months. Infants were classified as
uninfected if they met one of three criteria: 1/virus-specific IgG
and IgM levels were both undetectable at nine months and IgM
levels remained undetectable at eleven months, or 2/virus-specific
IgG and IgM levels were both undetectable at eleven months.
Infants for whom none of the above criteria could be met were
unclassified.
Virus-specific antibody levels were measured using ETI-VCA-G
and ETI-EBV-M Reverse ELISAs (Diasorin), which detect IgG
and IgM respectively to the viral capsid antigen (VCA). Infection
with CMV was diagnosed using the ELICYTOK-G Plus ELISA
(Diasorin) to detect IgG and either the ETI-CYTOK-M Reverse
Plus (Diasorin) or the Cytomegalovirus IgM CAPTIATM ELISA
(Trinity Biotech) to detect IgM.
Diagnosis for exposure to malaria parasites
Exposure to malaria was assessed by testing for the presence of
IgG antibody specific for two merozoite surface antigens, apical
membrane antigen 1 (AMA1) [34] and the two allelic types of
merozoite surface antigen 2 (MSP2) [35] using an ELISA method
as previously described [36]. Samples were classified as seropos-
itive if the optical density reading was above 3 standard deviations
of the mean value obtained by testing 20 sera from non-immune
tourists visiting The Gambia [33].
EBV & CMV Alter Ab. Responses
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Measurement of vaccine responses
Antibody responses to measles and meningococcus were
measured using the serum samples collected at eleven months of
age. Responses to meningococcus were quantified with an ELISA
adapted from a previously published protocols [37]. Standards
were prepared from reference serum CDC 1992 (NIBSC) at 1/100
for meningococcus A and 1/200 for meningococcus C, and eight
doubling dilutions of triplicate preparations were carried out for
each microplate, enabling results to be expressed as mg ml21.
Anti-measles antibody response was measured using the
haemagglutinin antibody inhibition assay (HAI) [38], and
calibrated against the second WHO standard. Assay sensitivity
was 15.6 mIU and minimum detectable value was 31.2 mIU.
Results are expressed as the log2 titre at which no haemaggluti-
nation was observed.
Assessment of EBV viral load
Samples were collected from 40 of the 43 EBV-seropositive
infants at eleven months of age. Aliquots of 200 ml of blood were
centrifuged at 2000 g for 5 min, plasma was removed and DNA
was isolated into 50 ml using the DNA Mini Kit reagents (Qiagen).
Positive control EBV DNA was extracted from B95-8 cells [39]
and Namalwa cells [40] using similar methods. The DNA
concentration of the samples was determined by UV spectropho-
tometry. The number of EBV genome copies in the DNA samples
was determined by real-time PCR. Briefly, 5 ml of DNA (1–5 ng/
ml) was included in a 25 ml reaction using the manufacturer’s
protocol (Qiagen Quantitect Virus kit). After a 10 min step at
95uC step to activate the polymerase, cycling (40 cycles) was
performed. Cycling (40 repeats) (15 s at 95uC, followed by 60 s at
60uC with data acquisition at either 470 nm source, 510 nm
Figure 1. Study Design. A Study design showing times at which samples were collected, EBV and CMV serology was carried out, vaccines were
administered and vaccine-specific responses were measured. B numbers of infants in the cohort and involved in analysis, and numbers infected with
EBV and CMV at nine and eleven months.
doi:10.1371/journal.pone.0014013.g001
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detection for FAM (EBV BALF5 probe) or 530 nm source,
555 nm detection for JOE (B2M probe). The primers and probes
are described in Table 1. The EBV genome number in test
samples was quantified relative to B95-8 and Namalwa DNA and
the EBV copy number per cell in the test samples was expressed
relative to the b-2 microglobulin gene [41]. The lower limit of
detection was four EBV copies in 5 ml DNA sample ( = 50 ml
original blood volume).
Statistical analysis
Association for infection with CMV and EBV was quantified
using Pearson’s chi-square test. Differences in the log10 trans-
formed vaccine response between CMV and EBV infection status
(and their interaction) were tested using linear regression adjusting
for the possible confounding effect of malaria infection. Due to the
high proportion of zero IgM responses to meningococcus C, the
responses were dichotomised around 0.10 mg ml-1and analysed
using logistic regression.
The HAI titres were categorized into 8 groups and ordinal
logistic regression was used to study the association with EBV and
CMV infections status, allowing for the possible confounding effect
of pre-vaccination measles antibody.
As the meningococcal ELISAs generated continuous data, they
were compared to EBV viral load by ANCOVA using CMV
serostatus as a fixed factor. If CMV serostatus was non-significant,
EBV viral load was compared to the antibody level by Spearman’s
correlation coefficient, and the four derived significances were
corrected for multiplicity by the step-down Bonferroni method.
Linear regression was used to test for the association between
EBV viral load and anti-meningococcus IgG and IgM adjusting
for CMV serostatus.
Analyses were performed using Stata 11 (Statacorp) and Matlab
7.4 (The MathWorks Inc). Differences were considered significant
at p,0.05.
Results
Analyses were restricted to the 178 subjects who were bled and
vaccinated at 9 months of age and who had antibody data at 11
months of age.
More infants were infected with CMV than EBV
CMV infection was usually earlier than EBV (Fig. 1). At nine
months, 115 of 173 (66%) classifiable subjects were CMV-infected
as opposed to 30 of 166 EBV-infected subjects. 10% of the CMV
uninfected subjects and 8% of the EBV uninfected subjects were
infected between 9 and 11 months of age. No significant
associations between seropositivity for CMV and EBV were found.
Few infants had been exposed to malaria or measles
At nine months, 30 of 176 (17%) samples tested were
seropositive for malaria. Seropositivity for malaria was not
associated with seropositivity for CMV or EBV.
Seropositivity for measles was uncommon before vaccination,
with only six of 178 (3.4%) infants tested immediately before
vaccination having a detectable level of haemagglutinating
antibody activity.
EBV infection was associated with low antibody
responses to meningococcus polysaccharide
There were no significant statistical interactions between the
effects of EBV and CMV on any of the responses to
meningococcus measured.
Levels of IgG and IgM to meningococcus A and C at 11 months
were compared by EBV serostatus at the time the vaccine was
administered at nine months. IgG responses were significantly
lower in EBV+ infants (p,0.05). However, there were no
detectable differences between EBV+ and EBV2 infants in the
anti-meningococcus A or C IgM levels (Table 2). When levels of
IgG and IgM to meningococcus A and C were compared by EBV
serostatus at the time of sampling at eleven months, both IgG and
IgM concentrations were lower in EBV+ infants (p,0.01) (Table 3).
Infection with CMV at either time of vaccination or at time of
sampling was not associated with anti-meningococcus antibody
levels at 11 months (Table 2, Table 3), and none of the responses
correlated with EBV viraemia at 11 months of age (data not shown).
Following these initial analyses, we then performed several tests
of the robustness of our analytic approach.
The majority of subjects who could not be classified had
detectable levels of IgG to CMV or EBV, but at levels lower than
in the umbilical cord blood. In order to test whether the results
could have been biased by failure to classify infants that were
actually uninfected, we repeated the regression analysis with all
unclassified infants as uninfected, and found that the associations
still remained significant (data not shown).
Eleven infants seroconverted for EBV between 9 and 11
months, and six seroconverted for CMV though none serocon-
verted for both To establish whether the difference between EBV-
infected and uninfected infants was due to the effect of infection
between the time of vaccination and sampling, we repeated the
regression analysis excluding any infants that seroconverted
between the two sampling times. The significant associations
remained the same as in the original analysis (data not shown).
To test whether malaria infection had any effect on anti-
meningococcus antibody levels, we repeated the regression
analysis with seropositivity to P. falciparum, defined as a detectable
response to any of the three antigens tested, as a factor. We found
no effect on the associations (data not shown).
EBV infection predicted low antibody responses to
measles unless there was concurrent CMV infection
There were significant interactions between the effects of EBV
and CMV infection on the anti-measles antibody response, so it
was inappropriate to perform multiple comparisons on the four
possible groups.
The same trends were apparent whether the infants were
classified by CMV and EBV serostatus at the time of vaccination
at nine months or the time of antibody measurement at eleven
Table 1. Primers used for quantification of EBV by real-time
PCR.
Name Function Sequence (59 to 39)
mo 052 EBV BALF5 forward
primer
CCTTTGGCGCGGATCCTC
mo 053 EBV BALF5 reverse
primer
TCCTTCTTGGCTAGTCTGTTGAC
mo 054 EBV BALF5 probe
59 6-FAM, 39 TAMRA
CATCAAGAAGCTGCTGGCGGCC
mo 055 B2M forward primer GGGAATTGATTTGGGAGAGCATC
mo 056 B2M reverse primer AGGTCCTGGCTCTACAATTTACTAA
mo 057 B2M probe
59 HEX, 39 TAMRA
AGTGTGACTGGGCAGATCATCCACCTTC
doi:10.1371/journal.pone.0014013.t001
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months. In both cases, antibody levels of the EBV+CMV2 infants
were considerably lower than those of any of the other three
groups, while differences between the other three groups were
small (Fig. 2).
The EBV+CMV2 group accounted for only 8 of the 161 (5.0%)
classifiable infants at nine months and 13 of 159 (8.2%) at eleven
months. The median log (base 2) HAI titre of the EBV+CMV2
infants was 2.5 as compared to 4.0 among EBV2CMV2 infants
classified by serostatus at nine months. The difference based on
serostatus at eleven months was smaller, but the median inhibiting
titre was 3.0 among EBV+CMV2 infants compared to 4.0 among
EBV2CMV2 infants.
Table 2. Antibody responses to meningococcus A and C, grouped by EBV/CMV serostatus at nine months.
Meningococcus strain Antibody isotype Group n Median (mg ml21) IQR P*
A IgG EBV2 136 2.05 1.30–3.92 0.03
A IgG EBV+ 30 1.40 0.80–2.31
A IgM EBV2 136 1.29 0.68–2.33 0.10
A IgM EBV+ 30 0.97 0.35–1.74
C IgG EBV2 136 3.20 1.59–6.80 0.04
C IgG EBV+ 30 2.47 1.21–3.86
C IgM EBV2 136 0.10 0.01–0.19 0.08
C IgM EBV+ 30 0.08 0.02–0.12
A IgG CMV2 58 2.00 1.40–4.41 0.12
A IgG CMV+ 115 1.75 1.16–3.56
A IgM CMV2 58 1.30 0.69–2.36 0.55
A IgM CMV+ 115 1.13 0.58–2.27
C IgG CMV2 58 3.67 1.77–6.63 0.28
C IgG CMV+ 115 2.68 1.35–5.63
C IgM CMV2 58 0.09 0.01–0.19 0.83
C IgM CMV+ 115 0.09 0.02–0.17
*Calculated by linear regression model. Significant values in bold.
Infection with EBV at time of vaccine administration at nine months predicts reduced antibody responses to both meningococcus A and C, but infection with CMV has
no effect. Groups refer to the CMV and EBV serostatus at the time the vaccine was administered at nine months.
doi:10.1371/journal.pone.0014013.t002
Table 3. Antibody responses to meningococcus A and C, grouped by EBV/CMV serostatus at eleven months.
Meningococcus strain Antibody isotype Group n Median (mg ml21) IQR P*
A IgG EBV2 124 2.15 1.35–4.13 0.003
A IgG EBV+ 41 1.43 0.90–2.31
A IgM EBV2 124 1.38 0.71–2.44 0.002
A IgM EBV+ 41 0.92 0.32–1.30
C IgG EBV2 124 3.44 1.75–7.44 0.006
C IgG EBV+ 41 2.41 1.19–3.80
C IgM EBV2 124 0.11 0.02–0.19 0.01
C IgM EBV+ 41 0.07 0.00–0.12
A IgG CMV2 51 2.03 1.31–4.44 0.08
A IgG CMV+ 121 1.86 1.20–3.56
A IgM CMV2 51 1.35 0.67–2.46 0.39
A IgM CMV+ 121 1.13 0.61–2.25
C IgG CMV2 51 3.61 1.95–6.19 0.26
C IgG CMV+ 121 2.70 1.37–6.18
C IgM CMV2 51 0.09 0.01–0.19 0.86
C IgM CMV+ 121 0.09 0.02–0.17
*Calculated by linear regression model. Significant values in bold.
Infection with EBV at eleven months predicts reduced antibody responses to both meningococcus A and C, but infection with CMV has no effect. Groups refer to EBV
and CMV serostatus at the time of sampling at 11 months.
doi:10.1371/journal.pone.0014013.t003
EBV & CMV Alter Ab. Responses
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e14013
CMV infection alone showed little effect on antibody titre, but
appeared to offset the reduced antibody response associated with
EBV as the median titre among EBV+CMV+ infants was 5.0 both
at nine and eleven months (Fig. 2).
Incorporating pre-vaccination measles antibody titre into the
regression model had no effect on the associations between CMV
and EBV with anti-measles antibodies, or the interaction between
CMV and EBV, and neither the presence nor the titre of pre-
vaccination anti-measles antibodies was associated with anti-
measles antibodies in any of the groups at 11 months.
Discussion
We found that EBV infection prior to or shortly after
vaccination at 9 months of age predicted lower antibody responses
to both the T-cell-dependent measles and T-cell-independent
meningococcus polysaccharide antigens, but that co-infection with
CMV was associated with responses equivalent to those found in
uninfected infants.
We can only speculate on the immune mechanisms underlying
these interactions as the study focussed on antibody measure-
ments. However several mechanisms of interaction between viral
infections have been described. For instance, one virus may induce
an immune response that inhibits growth of another [42,43], or
specific immune responses induced by one virus may cross-react
with epitopes expressed by another [44].
The lower antibody responses in EBV-infected infants are
consistent with the finding that EBV infection of B-cells induces
mutations that may interfere with antibody production [18]. Work
on mouse models showed that the immune system can only
support a finite number of antibody producing cells [45], so it is
also possible that EBV-induced expansion reduces the available
niches for vaccine-specific antibody producing cells.
Co-infection with CMV appeared to return antibody levels to
the T-cell-dependent haemmaglutinin to levels found in EBV2
infants. As there was no effect of CMV infection on antibody to
the T-cell-independent meningococcus vaccine, this suggests
restoration was mediated through T-cells. In The Gambia, we
have previously found that CMV infection drives CD4 T-cell
differentiation in infants and that cellular responses to CMV
correlate with the antibody response to measles vaccine [26],
which suggests that exposure to CMV may enhance antibody
production through non-specific upregulation of CD4 T-cell
mediated help. Studies in The Gambia [26] and Malawi [46]
have shown that CMV infection is associated with a relatively high
proportion of memory cells in both the CD4 and CD8 T-cell
compartments, which accords with our findings. These putative
interactions of CMV with vaccines need to be studied on a larger
scale in early infancy when the incidence of CMV is highest and
vaccination most intense.
We were unable to distinguish the effects of infection with EBV
and CMV at time of vaccination from the effects at time of
sampling so could not establish whether low vaccine antibody
levels in EBV-infected infants are programmed at the time of
infection or whether infections after vaccination are able to down
regulate current antibody production. In either case, approxi-
mately 20% of infants were infected with EBV at nine months and
consequently subject to lower immune response which is a
substantial number, even if post-vaccination EBV infection does
not have the same downregulatory effects.
It is unlikely that EBV infection alone is sufficient explanation
for reduced efficacy of measles vaccine in Africa, as only 10% of
Figure 2. Infection with EBV but not CMV downregulates antibody responses to measles. Infection with EBV is associated with reduced
antibody responses to measles unless infants are coinfected with CMV. Plots of serum haemagglutinin-inhibiting activity at eleven months of age,
plotted against the serostatus at A the time of vaccination at nine months of age and B the time of sampling at eleven months of age. Titres are
expressed as log2. Grey bars indicate medians. Significances refer to the statistical interaction between the effects of EBV and CMV infection.
doi:10.1371/journal.pone.0014013.g002
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infants were EBV+CMV2. However the magnitude of the
reduction in antibody responses suggests that EBV may be a
contributing factor along with early age of immunisation,
persistence of maternal antibody [47] and intense exposure during
measles outbreaks due to overcrowding [48].
Malaria has been associated with immunosuppression of
responses to viral infection [17,49] and the meningococcal
polysaccharide and Haemophilus influenzae vaccines [2,3]. However
the lack of association between low level malaria exposure and
CMV or EBV infection in this cohort, or between malaria
exposure and antibody response to vaccines makes it unlikely that
malaria infection confounded the association between antibody
levels and CMV and EBV infection in this cohort. Together with
the low HIV prevalence and lack of concurrent disease outbreaks,
it is unlikely that another infection was behind the observed
differences. Due to shortage of sera we could not measure pre-
vaccination meningococcal antibody concentrations. However,
previous studies in the region have shown that maternal antibody
decays quickly and that infants have undetectable or very low
levels [50] and very low carriage rates [51], so past or intercurrent
infection with meningococci are unlikely to have influenced our
results.
Our exploratory study was relatively limited in size and cannot
provide a mechanistic explanation for the potentially important
findings. Larger studies will be necessary to establish whether
CMV or EBV infection bears on vaccine efficacy or enhances
susceptibility to invasion by polysaccharide-encapsulated bacteria
such as Streptococcus pneumoniae or Neisseria meningitidis, which are
common in this region. Furthermore, understanding the interac-
tion of these common early life infections with the infant immune
system may shed light on the non-specific effects of vaccines
reported in West Africa [52,53].
Conclusions
Infection with EBV reduced antibody responses to the T-cell
independent meningococcal polysaccharide vaccines while infec-
tion with CMV had no effect. Infection with EBV alone reduced
the antibody response to the live measles vaccine, but co-infection
with CMV reversed the effects of EBV and elevated the antibody
response to levels similar to those of infants infected with neither
virus.
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